Inhalation gases or gaseous mediators as neuroprotectants for cerebral ischaemia

Current Drug Targets

Volumn 14, Issue 1, 2013, Pages 56-73

  Sutherland, Brad A ^a   Harrison, Joanne C ^b   Nair, Shiva M ^c   Sammut, Ivan A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

Carbon monoxide; Inhalation therapy; Ischaemic stroke; Neuroprotection; Nitric oxide; Oxygen

Indexed keywords

ARGON; CARBON MONOXIDE; CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; DEXMEDETOMIDINE; GLYCERYL TRINITRATE; HELIUM; HYDROGEN; HYDROGEN SULFIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; NITROUS OXIDE; NORPHENAZONE; OXYGEN; PROTEIN BCL 2; XENON;

BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; BRAIN ISCHEMIA; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; EXCITOTOXICITY; GAS; HUMAN; HYPERBARIC OXYGEN; HYPEROXIA; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN AFFINITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRESSURE GRADIENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84876697660     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804806433     Document Type: Review

References (220)

1. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: Translation from the bench to the bedside. Int J Stroke 2012; 7(5): 407-18.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13): 1317-29.
3. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379(9834): 2364-72.
4. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59(3): 467-77.
5. Fisher M. New approaches to neuroprotective drug development. Stroke 2011; 42(1 Suppl): S24-7.
6. Gianetti J, Del Sarto P, Bevilacqua S, et al. Supplemental nitric oxide and its effect on myocardial injury and function in patients undergoing cardiac surgery with extracorporeal circulation. J Thorac Cardiovasc Surg 2004; 127(1): 44-50.
7. Nakao A, Kaczorowski DJ, Wang Y, et al. Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant 2010; 29(5): 544-53.
8. Oei GT, Huhn R, Heinen A, et al. Helium-induced cardioprotection of healthy and hypertensive rat myocardium in vivo. Eur J Pharmacol 2012; 684(1-3): 125-31.
9. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1(4): 338-44.
10. Leucuta SE. Drug Delivery Systems With Modified Release for Systemic and Biophase Biovailability. Curr Clin Pharmacol 2012.
11. Britton GL, Kim H, Kee PH, et al. In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes. Circulation 2010; 122(16): 1578-87.
12. Barach AL. Use of helium as a new therapeutic gas. Proc Soc Exp Biol Med 1934; 32: 462-4.
13. Behnke AR, Yarbrough OD. Respiratory resistance, oil-water solubility, and mental effects of argon, compared with helium and nitrogen. Am J Physiol 1939; 126: 409-15.
14. Myers TR. Therapeutic gases for neonatal and pediatric respiratory care. Respir Care 2003; 48(4): 399-422; discussion 3-5.
15. Gjedde A. The pathways of oxygen in brain. I. Delivery and metabolism of oxygen. Adv Exp Med Biol 2005; 566: 269-75.
16. Calvert JW, Cahill J, Zhang JH. Hyperbaric oxygen and cerebral physiology. Neurol Res 2007; 29(2): 132-41.
17. Michalski D, Hartig W, Schneider D, Hobohm C. Use of normobaric and hyperbaric oxygen in acute focal cerebral ischemia-a preclinical and clinical review. Acta Neurol Scand 2011; 123(2): 85-97.
18. Boerema I, Meyne NG, Brummelkamp WH, et al. [Life without blood]. Ned Tijdschr Geneeskd 1960; 104: 949-54.
19. Jacobson I, Lawson DD. The Effect of Hyperbaric Oxygen on Experimental Cerebral Infarction in the Dog. With Preliminary Correlations of Cerebral Blood Flow at 2 Atmospheres of Oxygen. J Neurosurg 1963; 20: 849-59.
20. Chang CF, Niu KC, Hoffer BJ, Wang Y, Borlongan CV. Hyperbaric oxygen therapy for treatment of postischemic stroke in adult rats. Exp Neurol 2000; 166(2): 298-306.
21. Veltkamp R, Siebing DA, Heiland S, et al. Hyperbaric oxygen induces rapid protection against focal cerebral ischemia. Brain Res 2005; 1037(1-2): 134-8.
22. Yin D, Zhou C, Kusaka I, et al. Inhibition of apoptosis by hyperbaric oxygen in a rat focal cerebral ischemic model. J Cereb Blood Flow Metab 2003; 23(7): 855-64.
23. Yin W, Badr AE, Mychaskiw G, Zhang JH. Down regulation of COX-2 is involved in hyperbaric oxygen treatment in a rat transient focal cerebral ischemia model. Brain Res 2002; 926(1-2): 165-71.
24. Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology 2002; 58(6): 945-52.
25. Eschenfelder CC, Krug R, Yusofi AF, et al. Neuroprotection by oxygen in acute transient focal cerebral ischemia is dose dependent and shows superiority of hyperbaric oxygenation. Cerebrovasc Dis 2008; 25(3): 193-201.
26. Veltkamp R, Warner DS, Domoki F, Brinkhous AD, Toole JF, Busija DW. Hyperbaric oxygen decreases infarct size and behavioral deficit after transient focal cerebral ischemia in rats. Brain Res 2000; 853(1): 68-73.
27. Badr AE, Yin W, Mychaskiw G, Zhang JH. Dual effect of HBO on cerebral infarction in MCAO rats. Am J Physiol Regul Integr Comp Physiol 2001; 280(3): R766-70.
28. Lou M, Eschenfelder CC, Herdegen T, Brecht S, Deuschl G. Therapeutic window for use of hyperbaric oxygenation in focal transient ischemia in rats. Stroke 2004; 35(2): 578-83.
29. Gunther A, Kuppers-Tiedt L, Schneider PM, et al. Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischaemia. Eur J Neurosci 2005; 21(11): 3189-94.
30. Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 2007; 27(9): 1632-42.
31. Henninger N, Kuppers-Tiedt L, Sicard KM, Gunther A, Schneider D, Schwab S. Neuroprotective effect of hyperbaric oxygen therapy monitored by MR-imaging after embolic stroke in rats. Exp Neurol 2006; 201(2): 316-23.
32. Lou M, Zhang H, Wang J, et al. Hyperbaric oxygen treatment attenuated the decrease in regional glucose metabolism of rats subjected to focal cerebral ischemia: a high resolution positron emission tomography study. Neuroscience 2007; 146(2): 555-61.
33. Miljkovic-Lolic M, Silbergleit R, Fiskum G, Rosenthal RE. Neuroprotective effects of hyperbaric oxygen treatment in experimental focal cerebral ischemia are associated with reduced brain leukocyte myeloperoxidase activity. Brain Res 2003; 971(1): 90-4.
34. Schabitz WR, Schade H, Heiland S, et al. Neuroprotection by hyperbaric oxygenation after experimental focal cerebral ischemia monitored by MRI. Stroke 2004; 35(5): 1175-9.
35. Xue L, Yu Q, Zhang H, Liu Y, Wang C, Wang Y. Effect of large dose hyperbaric oxygenation therapy on prognosis and oxidative stress of acute permanent cerebral ischemic stroke in rats. Neurol Res 2008; 30(4): 389-93.
36. Gu GJ, Li YP, Peng ZY, et al. Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregu lation of hypoxia-inducible factor-1alpha and erythropoietin in rats. J Appl Physiol 2008; 104(4): 1185-91.
37. Li JS, Zhang W, Kang ZM, et al. Hyperbaric oxygen preconditioning reduces ischemia-reperfusion injury by inhibition of apoptosis via mitochondrial pathway in rat brain. Neuroscience 2009; 159(4): 1309-15.
38. Nonaka Y, Shimazawa M, Yoshimura S, Iwama T, Hara H. Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice. Neurosci Lett 2008; 441(2): 224-8.
39. Imai K, Mori T, Izumoto H, Takabatake N, Kunieda T, Watanabe M. Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. Neurol Med Chir (Tokyo) 2006; 46(8): 373-8; discussion 8.
40. Fujiwara N, Murata Y, Arai K, et al. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neurosci 2009; 10: 79.
41. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. J Cereb Blood Flow Metab 2009; 29(1): 119-29.
42. Michalski D, Kuppers-Tiedt L, Weise C, et al. Long-term functional and neurological outcome after simultaneous treatment with tissue-plasminogen activator and hyperbaric oxygen in early phase of embolic stroke in rats. Brain Res 2009; 1303: 161-8.
43. Ingvar DH, Lassen NA. Treatment of Focal Cerebral Ischemia with Hyperbaric Oxygen. Report of 4 Cases. Acta Neurol Scand 1965; 41: 92-5.
44. Neubauer RA, End E. Hyperbaric oxygenation as an adjunct therapy in strokes due to thrombosis. A review of 122 patients. Stroke 1980; 11(3): 297-300.
45. Anderson DC, Bottini AG, Jagiella WM, et al. A pilot study of hyperbaric oxygen in the treatment of human stroke. Stroke 1991; 22(9): 1137-42.
46. Rusyniak DE, Kirk MA, May JD, et al. Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study. Stroke 2003; 34(2): 571-4.
47. Helms AK, Whelan HT, Torbey MT. Hyperbaric oxygen therapy of cerebral ischemia. Cerebrovasc Dis 2005; 20(6): 417-26.
48. Nighoghossian N, Trouillas P, Adeleine P, Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke. A double-blind pilot study. Stroke 1995; 26(8): 1369-72.
49. Bennett MH, Wasiak J, Schnabel A, Kranke P, French C. Hyperbaric oxygen therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2005; (3): CD004954.
50. Singhal AB, Benner T, Roccatagliata L, et al. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 2005; 36(4): 797-802.
51. Roffe C, Ali K, Warusevitane A, et al. The SOS pilot study: a RCT of routine oxygen supplementation early after acute stroke-effect on recovery of neurological function at one week. PLoS One 2011; 6(5): e19113.
52. Beynon C, Sun L, Marti HH, Heiland S, Veltkamp R. Delayed hyperbaric oxygenation is more effective than early prolonged normobaric hyperoxia in experimental focal cerebral ischemia. Neurosci Lett 2007; 425(3): 141-5.
53. Stroke Trials Registry. The Internet Stroke Centre [cited 21/08/2012]; Available from: http://www.strokecenter.org/trials/
54. Hyperbaric Oxygen Therapy Induced Neuroplasticity in Post Stroke Patients Suffering Chronic Neurological Deficiencies. ClinicalTrialsgov [cited 21/08/2012]; Available from: http://clinicaltrials.gov/show/NCT00715897
55. Fischer BR, Palkovic S, Holling M, Wolfer J, Wassmann H. Rationale of hyperbaric oxygenation in cerebral vascular insult. Curr Vasc Pharmacol 2010; 8(1): 35-43.
56. Matchett GA, Martin RD, Zhang JH. Hyperbaric oxygen therapy and cerebral ischemia: neuroprotective mechanisms. Neurol Res 2009; 31(2): 114-21.
57. Zhang JH, Lo T, Mychaskiw G, Colohan A. Mechanisms of hyperbaric oxygen and neuroprotection in stroke. Pathophysiology 2005; 12(1): 63-77.
58. Buras JA, Reenstra WR. Endothelial-neutrophil interactions during ischemia and reperfusion injury: basic mechanisms of hyperbaric oxygen. Neurol Res 2007; 29(2): 127-31.
59. Huang ZX, Kang ZM, Gu GJ, et al. Therapeutic effects of hyperbaric oxygen in a rat model of endothelin-1-induced focal cerebral ischemia. Brain Res 2007; 1153: 204-13.
60. Sun L, Marti HH, Veltkamp R. Hyperbaric oxygen reduces tissue hypoxia and hypoxia-inducible factor-1 alpha expression in focal cerebral ischemia. Stroke 2008; 39(3): 1000-6.
61. Qin Z, Karabiyikoglu M, Hua Y, et al. Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia. Stroke 2007; 38(4): 1362-7.
62. Veltkamp R, Siebing DA, Sun L, et al. Hyperbaric oxygen reduces blood-brain barrier damage and edema after transient focal cerebral ischemia. Stroke 2005; 36(8): 1679-83.
63. Liu W, Hendren J, Qin XJ, Shen J, Liu KJ. Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 2009; 108(3): 811-20.
64. Liu W, Sood R, Chen Q, et al. Normobaric hyperoxia inhibits NADPH oxidase-mediated matrix metalloproteinase-9 induction in cerebral microvessels in experimental stroke. J Neurochem 2008; 107(5): 1196-205.
65. Veltkamp R, Bieber K, Wagner S, et al. Hyperbaric oxygen reduces basal lamina degradation after transient focal cerebral ischemia in rats. Brain Res 2006; 1076(1): 231-7.
66. Jerret SA, Jefferson D, Mengel CE. Seizures, H2O2 formation and lipid peroxydes in brain during exposure to oxygen under high pressure. Aerospace Med 1973; 44: 40-4.
67. Noda Y, McGeer PL, McGeer EG. Lipid peroxyde distribution in brain and the effect of hyperbaric oxygen. J Neurochem 1983; 40: 1329-32.
68. Li J, Liu W, Ding S, et al. Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. Brain Res 2008; 1210: 223-9.
69. Miller JD, Ledingham IM, Jennett WB. Effects of hyperbaric oxygen on intracranial pressure and cerebral blood flow in experimental cerebral oedema. J Neurol Neurosurg Psychiatry 1970; 33(6): 745-55.
70. Atochin DN, Demchenko IT, Astern J, Boso AE, Piantadosi CA, Huang PL. Contributions of endothelial and neuronal nitric oxide synthases to cerebrovascular responses to hyperoxia. J Cereb Blood Flow Metab 2003; 23(10): 1219-26.
71. Lassen NA, Palvolgyi R. Cerebral steal during hypercapnia and the inverse reaction during hypocapnia observed by the 133 xenon technique in man. Scand J Clin Lab Invest Suppl 1968; 102: XIII:D.
72. Shin HK, Dunn AK, Jones PB, et al. Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits periinfarct depolarizations in experimental focal ischaemia. Brain 2007; 130(Pt 6): 1631-42.
73. Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113(2942): 580-2.
74. Nakata Y, Goto T, Morita S. Clinical pharmacology of xenon. Int Anesthesiol Clin 2001; 39(2): 63-75.
75. Coburn M, Kunitz O, Baumert JH, et al. Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia. Br J Anaesth 2005; 94(2): 198-202.
76. Wilhelm S, Ma D, Maze M, Franks NP. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002; 96(6): 1485-91.
77. Petzelt C, Blom P, Schmehl W, Muller J, Kox WJ. Prevention of neurotoxicity in hypoxic cortical neurons by the noble gas xenon. Life Sci 2003; 72(17): 1909-18.
78. Petzelt C, Blom P, Schmehl W, Muller J, Kox WJ. Xenon prevents cellular damage in differentiated PC-12 cells exposed to hypoxia. BMC Neurosci 2004; 5: 55.
79. David HN, Haelewyn B, Rouillon C, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J 2008; 22(4): 1275-86.
80. Homi HM, Yokoo N, Ma D, et al. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 2003; 99(4): 876-81.
81. David HN, Leveille F, Chazalviel L, et al. Reduction of ischemic brain damage by nitrous oxide and xenon. J Cereb Blood Flow Metab 2003; 23(10): 1168-73.
82. Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides shortterm neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006; 37(2): 501-6.
83. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58(2): 182-93.
84. Zhuang L, Yang T, Zhao H, et al. The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. Crit Care Med 2012; 40(6): 1724-30.
85. Rajakumaraswamy N, Ma D, Hossain M, Sanders RD, Franks NP, Maze M. Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models. Neurosci Lett 2006; 409(2): 128-33.
86. Ma D, Hossain M, Pettet GK, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab 2006; 26(2): 199-208.
87. Limatola V, Ward P, Cattano D, et al. Xenon preconditioning confers neuroprotection regardless of gender in a mouse model of transient middle cerebral artery occlusion. Neuroscience 2010; 165(3): 874-81.
88. Luo Y, Ma D, Ieong E, et al. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology 2008; 109(5): 782-9.
89. Sanders RD, Franks NP, Maze M. Xenon: no stranger to anaesthesia. Br J Anaesth 2003; 91(5): 709-17.
90. Yang T, Zhuang L, Rei Fidalgo AM, et al. Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. PLoS One 2012; 7(5): e37020.
91. David HN, Haelewyn B, Risso JJ, Colloc'h N, Abraini JH. Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2010; 30(4): 718-28.
92. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003; 34(4): 1084-104.
93. Carlson AP, Brown AM, Zager E, et al. Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: a multicenter study. AJNR Am J Neuroradiol 2011; 32(7): 1315-20.
94. Laitio RM, Kaisti KK, Laangsjo JW, et al. Effects of xenon anesthesia on cerebral blood flow in humans: a positron emission tomography study. Anesthesiology 2007; 106(6): 1128-33.
95. Hartmann A, Dettmers C, Schuier FJ, Wassmann HD, Schumacher HW. Effect of stable xenon on regional cerebral blood flow and the electroencephalogram in normal volunteers. Stroke 1991; 22(2): 182-9.
96. Luttropp HH, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O. Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. A transoesophageal echocardiography and transcranial Doppler sonography study. Anaesthesia 1993; 48(12): 1045-9.
97. Sutherland BA, Papadakis M, Chen RL, Buchan AM. Cerebral blood flow alteration in neuroprotection following cerebral ischemia. J Physiol 2011; 589(17): 4105-14.
98. Banks P, Franks NP, Dickinson R. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology 2010; 112(3): 614-22.
99. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature 1998; 396(6709): 324.
100. Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. Comparison with isoflurane and ethanol. Anesthesiology 2000; 93(4): 1095-101.
101. Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T. The diverse actions of volatile and gaseous anesthetics on humancloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes. Anesthesiology 2002; 96(3): 699-704.
102. Liu W, Khatibi N, Sridharan A, Zhang JH. Application of medical gases in the field of neurobiology. Med Gas Res 2011; 1(1): 13.
103. Galley HF, Le Cras AE, Logan SD, Webster NR. Differential nitric oxide synthase activity, cofactor availability and cGMP accumulation in the central nervous system during anaesthesia. Br J Anaesth 2001; 86(3): 388-94.
104. Weber NC, Toma O, Wolter JI, et al. The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br J Pharmacol 2005; 144(1): 123-32.
105. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B. Mechanisms of xenon-and isoflurane-induced preconditioning-a potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway. Br J Pharmacol 2005; 146(3): 445-55.
106. Shu Y, Patel SM, Pac-Soo C, et al. Xenon pretreatment attenuates anesthetic-induced apoptosis in the developing brain in comparison with nitrous oxide and hypoxia. Anesthesiology 2010; 113(2): 360-8.
107. de Rossi LW, Horn NA, Stevanovic A, Buhre W, Hutschenreuter G, Rossaint R. Xenon modulates neutrophil adhesion molecule expression in vitro. Eur J Anaesthesiol 2004; 21(2): 139-43.
108. Dole M, Wilson FR, Fife WP. Hyperbaric hydrogen therapy: a possible treatment for cancer. Science 1975; 190(4210): 152-4.
109. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007; 13(6): 688-94.
110. Cai J, Kang Z, Liu K, et al. Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. Brain Res 2009; 1256: 129-37.
111. Cai J, Kang Z, Liu WW, et al. Hydrogen therapy reduces apoptosis in neonatal hypoxia-ischemia rat model. Neurosci Lett 2008; 441(2): 167-72.
112. Chen CH, Manaenko A, Zhan Y, et al. Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model. Neuroscience 2010; 169(1): 402-14.
113. Matchett GA, Fathali N, Hasegawa Y, et al. Hydrogen gas is ineffective in moderate and severe neonatal hypoxia-ischemia rat models. Brain Res 2009; 1259: 90-7.
114. Ono H, Nishijima Y, Adachi N, et al. A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 level. Med Gas Res 2012; 2(1): 21.
115. Pan Y, Zhang H, VanDeripe DR, Cruz-Flores S, Panneton WM. Heliox and oxygen reduce infarct volume in a rat model of focal ischemia. Exp Neurol 2007; 205(2): 587-90.
116. David HN, Haelewyn B, Chazalviel L, et al. Post-ischemic helium provides neuroprotection in rats subjected to middle cerebral artery occlusion-induced ischemia by producing hypothermia. J Cereb Blood Flow Metab 2009; 29(6): 1159-65.
117. Pan Y, Zhang H, Acharya AB, Cruz-Flores S, Panneton WM. The effect of heliox treatment in a rat model of focal transient cerebral ischemia. Neurosci Lett 2011; 497(2): 144-7.
118. Jawad N, Rizvi M, Gu J, et al. Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury. Neurosci Lett 2009; 460(3): 232-6.
119. Heinen A, Huhn R, Smeele KM, et al. Helium-induced preconditioning in young and old rat heart: impact of mitochondrial Ca(2+)-sensitive potassium channel activation. Anesthesiology 2008; 109(5): 830-6.
120. Pagel PS, Krolikowski JG, Shim YH, et al. Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg 2007; 105(3): 562-9.
121. Liu Y, Xue F, Liu G, et al. Helium preconditioning attenuates hypoxia/ischemia-induced injury in the developing brain. Brain Res 2011; 1376: 122-9.
122. Loetscher PD, Rossaint J, Rossaint R, et al. Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009; 13(6): R206.
123. Ryang YM, Fahlenkamp AV, Rossaint R, et al. Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats. Crit Care Med 2011; 39(6): 1448-53.
124. David HN, Haelewyn B, Degoulet M, Colomb DG, Jr., Risso JJ, Abraini JH. Ex vivo and in vivo neuroprotection induced by argon when given after an excitotoxic or ischemic insult. PLoS One 2012; 7(2): e30934.
125. Abraini JH, Kriem B, Balon N, Rostain JC, Risso JJ. Gammaaminobutyric acid neuropharmacological investigations on narcosis produced by nitrogen, argon, or nitrous oxide. Anesth Analg 2003; 96(3): 746-9, table of contents.
126. Xu J, Li C, Yin XH, Zhang GY. Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology 2008; 54(7): 1029-40.
127. Zhang F, Li C, Wang R, et al. Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion. Neuroscience 2007; 150(4): 938-49.
128. Erving HW. The Discoverer of Anaesthesia: Dr. Horace Wells of Hartford. Yale J Biol Med 1933; 5(5): 421-30.
129. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4(4): 460-3.
130. Haelewyn B, David HN, Rouillon C, et al. Neuroprotection by nitrous oxide: facts and evidence. Crit Care Med 2008; 36(9): 2651-9.
131. Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging 2005; 26(6): 947-56.
132. Ma D, Williamson P, Januszewski A, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology 2007; 106(4): 746-53.
133. Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS. Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine. Anesth Analg 2004; 99(3): 896-903, table of contents.
134. Smith I. Nitrous oxide in ambulatory anaesthesia: does it have a place in day surgical anaesthesia or is it just a threat for personnel and the global environment? Curr Opin Anaesthesiol 2006; 19(6): 592-6.
135. Pasternak JJ, McGregor DG, Lanier WL, et al. Effect of nitrous oxide use on long-term neurologic and neuropsychological outcome in patients who received temporary proximal artery occlusion during cerebral aneurysm clipping surgery. Anesthesio logy 2009; 110(3): 563-73.
136. Haelewyn B, David HN, Colloc'h N, Colomb DG, Jr., Risso JJ, Abraini JH. Interactions between nitrous oxide and tissue plasminogen activator in a rat model of thromboembolic stroke. Anesthesiology 2011; 115(5): 1044-53.
137. Benarroch EE. Nitric oxide: A pleiotropic signal in the nervous system. Neurology 2011; 77(16): 1568-76.
138. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-6.
139. Pinnock SB, Balendra R, Chan M, Hunt LT, Turner-Stokes T, Herbert J. Interactions between nitric oxide and corticosterone in the regulation of progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropsychopharmacology 2007; 32(2): 493-504.
140. Cheyuo C, Wu R, Zhou M, Jacob A, Coppa G, Wang P. Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 2011; 35(3): 258-65.
141. Sugimura T, Sako K, Tohyama Y, Yonemasu Y. Consecutive in vivo measurement of nitric oxide in transient forebrain ischemic rat under normothermia and hypothermia. Brain Res 1998; 808(2): 313-6.
142. Nair SM, Rahman RM, Clarkson AN, et al. Melatonin treatment following stroke induction modulates l-arginine metabolism. J Pineal Res 2011; 51(3): 313-23.
143. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-Larginine. J Cereb Blood Flow Metab 1996; 16(5): 981-7.
144. Murad F, Waldman S, Molina C, Bennett B, Leitman D. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation. Prog Clin Biol Res 1987; 249: 65-76.
145. Antl M, von Bruhl ML, Eiglsperger C, et al. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007; 109(2): 552-9.
146. Cui X, Chopp M, Zacharek A, Zhang C, Roberts C, Chen J. Role of endothelial nitric oxide synthetase in arteriogenesis after stroke in mice. Neuroscience 2009; 159(2): 744-50.
147. Suzuki M, Tabuchi M, Ikeda M, Tomita T. Concurrent formation of peroxynitrite with the expression of inducible nitric oxide synthase in the brain during middle cerebral artery occlusion and reperfusion in rats. Brain Res 2002; 951(1): 113-20.
148. Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 1994; 263(5149): 973-7.
149. Petegnief V, Font-Nieves M, Martin ME, Salinas M, Planas AM. Nitric oxide mediates NMDA-induced persistent inhibition of protein synthesis through dephosphorylation of eukaryotic initiation factor 4E-binding protein 1 and eukaryotic initiation factor 4G proteolysis. Biochem J 2008; 411(3): 667-77.
150. Nagasu H, Satoh M, Kidokoro K, et al. Endothelial dysfunction promotes the transition from compensatory renal hypertrophy to kidney injury after unilateral nephrectomy in mice. Am J Physiol Renal Physiol 2012; 302(11): F1402-8.
151. Willmot M, Gibson C, Gray L, Murphy S, Bath P. Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review. Free Radic Biol Med 2005; 39(3): 412-25.
152. Luo CX, Jin X, Cao CC, et al. Bidirectional regulation of neurogenesis by neuronal nitric oxide synthase derived from neurons and neural stem cells. Stem Cells 2010; 28(11): 2041-52.
153. Zhu DY, Liu SH, Sun HS, Lu YM. Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus. J Neurosci 2003; 23(1): 223-9.
154. Willmot M, Gray L, Gibson C, Murphy S, Bath PM. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide 2005; 12(3): 141-9.
155. Kuebler WM, Kisch-Wedel H, Kemming GI, et al. Inhaled nitric oxide induces cerebrovascular effects in anesthetized pigs. Neurosci Lett 2003; 348(2): 85-8.
156. Nagasaka Y, Buys ES, Spagnolli E, et al. Soluble guanylate cyclase-alpha1 is required for the cardioprotective effects of inhaled nitric oxide. Am J Physiol Heart Circ Physiol 2011; 300(4): H1477-83.
157. Terpolilli NA, Kim SW, Thal SC, et al. Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ Res 2012; 110(5): 727-38.
158. Bloch KD, Ichinose F, Roberts JD, Jr., Zapol WM. Inhaled NO as a therapeutic agent. Cardiovasc Res 2007; 75(2): 339-48.
159. Sare GM, Gray LJ, Wardlaw J, Chen C, Bath PM. Is lowering blood pressure hazardous in patients with significant ipsilateral carotid stenosis and acute ischaemic stroke? Interim assessment in the 'Efficacy of Nitric Oxide in Stroke' trial. Blood Press Monit 2009; 14(1): 20-5.
160. Ikuta T, Thatte HS, Tang JX, et al. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization. Arch Biochem Biophys 2011; 510(1): 53-61.
161. Montero-Huerta P, Hess DR, Head CA. Inhaled nitric oxide for treatment of sickle cell stroke. Anesthesiology 2006; 105(3): 619-21.
162. Harston GW, Sutherland BA, Kennedy J, Buchan AM. The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab 2010; 30(11): 1804-16.
163. Jia L, Bonaventura C, Bonaventura J, Stamler JS. Snitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 1996; 380(6571): 221-6.
164. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005; 115(5): 1232-40.
165. Salhany JM. Kinetics of reaction of nitrite with deoxy hemoglobin after rapid deoxygenation or predeoxygenation by dithionite measured in solution and bound to the cytoplasmic domain of band 3 (SLC4A1). Biochemistry 2008; 47(22): 6059-72.
166. Sheng H, Reynolds JD, Auten RL, et al. Pharmacologically augmented S-nitrosylated hemoglobin improves recovery from murine subarachnoid hemorrhage. Stroke 2011; 42(2): 471-6.
167. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61(2): 748-55.
168. Coburn RF, Blakemore WS, Forster RE. Endogenous carbon monoxide production in man. J Clin Invest 1963; 42: 1172-8.
169. Neto JS, Nakao A, Kimizuka K, et al. Protection of transplantinduced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol 2004; 287(5): F979-89.
170. Sammut IA, Foresti R, Clark JE, et al. Carbon monoxide is a major contributor to the regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Br J Pharmacol 1998; 125(7): 1437-44.
171. Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32(4): 497-504.
172. Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase. Cardiovasc Res 2006; 71(2): 393-401.
173. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest 2007; 117(2): 438-47.
174. Wang X, Wang Y, Kim HP, Nakahira K, Ryter SW, Choi AM. Carbon monoxide protects against hyperoxia-induced endothelial cell apoptosis by inhibiting reactive oxygen species formation. J Biol Chem 2007; 282(3): 1718-26.
175. Parfenova H, Neff RA, 3rd, Alonso JS, et al. Cerebral vascular endothelial heme oxygenase: expression, localization, and activation by glutamate. Am J Physiol Cell Physiol 2001; 281(6): C1954-63.
176. Steiger HJ, Hanggi D. Ischaemic preconditioning of the brain, mechanisms and applications. Acta Neurochir (Wien) 2007; 149(1): 1-10.
177. Bergeron M, Ferriero DM, Vreman HJ, Stevenson DK, Sharp FR. Hypoxia-ischemia, but not hypoxia alone, induces the expression of heme oxygenase-1 (HSP32) in newborn rat brain. J Cereb Blood Flow Metab 1997; 17(6): 647-58.
178. Sutherland BA, Rahman RM, Clarkson AN, Shaw OM, Nair SM, Appleton I. Cerebral heme oxygenase 1 and 2 spatial distribution is modulated following injury from hypoxia-ischemia and middle cerebral artery occlusion in rats. Neurosci Res 2009; 65(4): 326-34.
179. Zhou J, Wu PF, Wang F, Chen JG. Targeting gaseous molecules to protect against cerebral ischaemic injury: Mechanisms and prospects. Clin Exp Pharmacol Physiol 2012; 39(6): 566-76.
180. Zeynalov E, Shah ZA, Li RC, Dore S. Heme oxygenase 1 is associated with ischemic preconditioning-induced protection against brain ischemia. Neurobiol Dis 2009; 35(2): 264-9.
181. Zeynalov E, Dore S. Low doses of carbon monoxide protect against experimental focal brain ischemia. Neurotox Res 2009; 15(2): 133-7.
182. Wang B, Cao W, Biswal S, Dore S. Carbon monoxide-activated Nrf2 pathway leads to protection against permanent focal cerebral ischemia. Stroke 2011; 42(9): 2605-10.
183. England TJ, Bath PM, Sare GM, et al. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke 2010; 41(12): 2834-9.
184. Yabluchanskiy A, Sawle P, Homer-Vanniasinkam S, Green CJ, Foresti R, Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke. Crit Care Med 2012; 40(2): 544-52.
185. Mayr FB, Spiel A, Leitner J, et al. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med 2005; 171(4): 354-60.
186. Bathoorn E, Slebos DJ, Postma DS, et al. Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur Respir J 2007; 30(6): 1131-7.
187. Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients. ClinicalTrialsgov [cited 23/08/2012]; Available from: http://clinicaltrials.gov/ct2/show/NCT00531856
188. Study of Inhaling Carbon Monoxide to Treat Patients With Intestinal Paralysis After Colon Surgery. ClinicalTrialsgov [cited 23/08/2012]; Available from: http://clinicaltrials.gov/ct2/show/ NCT01050712
189. Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis. ClinicalTrialsgov [cited 23/08/2012]; Available from: http://clinicaltrials.gov/ct2/show/NCT01214187
190. Goldstein M. Carbon monoxide poisoning. J Emerg Nurs 2008; 34(6): 538-42.
191. Gorman D, Drewry A, Huang YL, Sames C. The clinical toxicology of carbon monoxide. Toxicology 2003; 187(1): 25-38.
192. Kim HP, Ryter SW, Choi AM. CO as a cellular signaling molecule. Annu Rev Pharmacol Toxicol 2006; 46: 411-49.
193. Ryter SW, Morse D, Choi AM. Carbon monoxide: to boldly go where NO has gone before. Sci STKE 2004; 2004(230): RE6.
194. Fiumana E, Parfenova H, Jaggar JH, Leffler CW. Carbon monoxide mediates vasodilator effects of glutamate in isolated pressurized cerebral arterioles of newborn pigs. Am J Physiol Heart Circ Physiol 2003; 284(4): H1073-9.
195. Jaggar JH, Leffler CW, Cheranov SY, Tcheranova D, E S, Cheng X. Carbon monoxide dilates cerebral arterioles by enhancing the coupling of Ca2+ sparks to Ca2+-activated K+ channels. Circ Res 2002; 91(7): 610-7.
196. Kanu A, Gilpin D, Fedinec AL, Leffler CW. Cyclooxygenase products stimulate carbon monoxide production by piglet cerebral microvessels. Exp Biol Med (Maywood) 2006; 231(2): 181-5.
197. Kanu A, Leffler CW. Carbon monoxide and Ca2+-activated K+ channels in cerebral arteriolar responses to glutamate and hypoxia in newborn pigs. Am J Physiol Heart Circ Physiol 2007; 293(5): H3193-200.
198. Kanu A, Leffler CW. Roles of glia limitans astrocytes and carbon monoxide in adenosine diphosphate-induced pial arteriolar dilation in newborn pigs. Stroke 2009; 40(3): 930-5.
199. Kanu A, Leffler CW. Arachidonic acid-and prostaglandin E2-induced cerebral vasodilation is mediated by carbon monoxide, independent of reactive oxygen species in piglets. Am J Physiol Heart Circ Physiol 2011; 301(6): H2482-7.
200. Kanu A, Whitfield J, Leffler CW. Carbon monoxide contributes to hypotension-induced cerebrovascular vasodilation in piglets. Am J Physiol Heart Circ Physiol 2006; 291(5): H2409-14.
201. Meilin S, Rogatsky GG, Thom SR, Zarchin N, Guggenheimer-Furman E, Mayevsky A. Effects of carbon monoxide on the brain may be mediated by nitric oxide. J Appl Physiol 1996; 81(3): 1078-83.
202. Dallas ML, Boyle JP, Milligan CJ, et al. Carbon monoxide protects against oxidant-induced apoptosis via inhibition of Kv2.1. FASEB J 2011; 25(5): 1519-30.
203. Mitchell CW, Davenport SJ. Hydrogen sulphide literature. Public Health Rep 1924; 39(1): 1-13.
204. Hu LF, Lu M, Hon Wong PT, Bian JS. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal 2011; 15(2): 405-19.
205. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996; 16(3): 1066-71.
206. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 2009; 30(10): 1523-34.
207. Ren C, Du A, Li D, Sui J, Mayhan WG, Zhao H. Dynamic change of hydrogen sulfide during global cerebral ischemia-reperfusion and its effect in rats. Brain Res 2010; 1345: 197-205.
208. Tay AS, Hu LF, Lu M, Wong PT, Bian JS. Hydrogen sulfide protects neurons against hypoxic injury via stimulation of ATPsensitive potassium channel/protein kinase C/extracellular signalregulated kinase/heat shock protein 90 pathway. Neuroscience 2010; 167(2): 277-86.
209. Li Z, Wang Y, Xie Y, Yang Z, Zhang T. Protective effects of exogenous hydrogen sulfide on neurons of hippocampus in a rat model of brain ischemia. Neurochem Res 2011; 36(10): 1840-9.
210. Wong PT, Qu K, Chimon GN, et al. High plasma cyst(e)ine level may indicate poor clinical outcome in patients with acute stroke: possible involvement of hydrogen sulfide. J Neuropathol Exp Neurol 2006; 65(2): 109-15.
211. Qu K, Chen CP, Halliwell B, Moore PK, Wong PT. Hydrogen sulfide is a mediator of cerebral ischemic damage. Stroke 2006; 37(3): 889-93.
212. Kida K, Yamada M, Tokuda K, et al. Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. Antioxid Redox Signal 2011; 15(2): 343-52.
213. Reiffenstein RJ, Hulbert WC, Roth SH. Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 1992; 32: 109-34.
214. Lu M, Choo CH, Hu LF, Tan BH, Hu G, Bian JS. Hydrogen sulfide regulates intracellular pH in rat primary cultured glia cells. Neurosci Res 2010; 66(1): 92-8.
215. Hu LF, Wong PT, Moore PK, Bian JS. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 2007; 100(4): 1121-8.
216. Kabil O, Banerjee R. Redox biochemistry of hydrogen sulfide. J Biol Chem 2010; 285(29): 21903-7.
217. Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J 2004; 18(10): 1165-7.
218. Hu LF, Lu M, Wu ZY, Wong PT, Bian JS. Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol 2009; 75(1): 27-34.
219. Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun 2000; 267(1): 129-33.
220. Li L, Bhatia M, Moore PK. Hydrogen sulphide-a novel mediator of inflammation? Curr Opin Pharmacol 2006; 6(2): 125-9.